Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients
NCT04864366
·
clinicaltrials.gov ↗
UNKNOWN
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Chronic Hepatitis B
Interventions
DRUG:
Tenofovir Alafenamide 25 MG [Vemlidy]
Sponsor
Huashan Hospital